Schmitz Norbert, Eapen Mary, Horowitz Mary M, Zhang Mei-Jie, Klein John P, Rizzo J Douglas, Loberiza Fausto R, Gratwohl Alois, Champlin Richard E
Department of Hematology, Asklepios Klinik St Georg, Hamburg, Germany.
Blood. 2006 Dec 15;108(13):4288-90. doi: 10.1182/blood-2006-05-024042. Epub 2006 Aug 31.
We previously compared outcomes after allogeneic peripheral-blood stem cell (PBSC) and bone marrow (BM) transplantation in 706 patients with leukemia. We obtained long-term follow up on 413 of 491 patients who were alive at the time of the initial report: 141 PBSC and 272 BM recipients. Chronic graft-versus-host disease (GVHD) was more frequent after PBSC compared to BM transplantation (RR 1.65, P < .001) yet relapse rates were similar in both groups. Leukemia-free survival rates were higher after PBSC than BM transplantation for patients with advanced chronic myeloid leukemia (33% versus 25%) but lower for those in first chronic phase (41% versus 61%) due to higher rates of late transplant-related mortality. Leukemia-free survival was similar after PBSC and BM transplantation for acute leukemia. These data represent the early experience with PBSC grafts. Long-term outcomes in recipients of more recent transplants are required to better evaluate the role of PBSC grafts relative to BM transplantation.
我们之前比较了706例白血病患者接受异基因外周血干细胞（PBSC）移植和骨髓（BM）移植后的结局。我们对初次报告时存活的491例患者中的413例进行了长期随访：141例接受PBSC移植的患者和272例接受BM移植的患者。与BM移植相比，PBSC移植后慢性移植物抗宿主病（GVHD）更为常见（相对危险度1.65，P <.001），但两组的复发率相似。对于晚期慢性髓性白血病患者，接受PBSC移植后的无白血病生存率高于BM移植（33%对25%），但对于处于慢性期的患者，由于移植相关晚期死亡率较高，接受PBSC移植后的无白血病生存率低于BM移植（41%对61%）。对于急性白血病，PBSC移植和BM移植后的无白血病生存率相似。这些数据代表了PBSC移植物的早期经验。需要对近期移植受者的长期结局进行研究，以更好地评估PBSC移植物相对于BM移植的作用。
